Jefferies Boosts Target on ABIOMED (ABMD) to $28 on Growth Prospects

Jefferies boosted its price target on ABIOMED (NASDAQ: ABMD) from $25 to $28 while maintaining its Buy rating.

The firm comments, "We recently met with ABMD and our confidence in the prospects for Impella adoption continues to grow. The convergence of a number of positive factors (guideline inclusion, clinical publications, new products (cVAD, right side pump, Symphony), new console, pending CPT code, and Japan launch) suggests Impella is still in the very early part of its growth curve."

For an analyst ratings summary and ratings history on ABIOMED click here. For more ratings news on ABIOMED click here.

Shares of ABIOMED closed at $21.40 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'